|
Roche drug cuts asthma attacks, improves lung function -study
Reuters The biotech drug lebrikizumab, which was developed by Roche Holding's Genentech unit, was tested at three doses in patients whose asthma was not sufficiently controlled even with high-dose, inhaled corticosteroids and a second asthma-controlling … |
View full post on asthma – Google News